AXSM vs. BHC, PBH, XENE, FOLD, IDYA, RARE, BHVN, ARWR, HCM, and ACAD
Should you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Bausch Health Companies (BHC), Prestige Consumer Healthcare (PBH), Xenon Pharmaceuticals (XENE), Amicus Therapeutics (FOLD), IDEAYA Biosciences (IDYA), Ultragenyx Pharmaceutical (RARE), Biohaven (BHVN), Arrowhead Pharmaceuticals (ARWR), HUTCHMED (HCM), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical preparations" industry.
Axsome Therapeutics (NASDAQ:AXSM) and Bausch Health Companies (NYSE:BHC) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, community ranking, dividends, valuation, institutional ownership and earnings.
Axsome Therapeutics presently has a consensus target price of $119.67, indicating a potential upside of 66.88%. Bausch Health Companies has a consensus target price of $12.50, indicating a potential upside of 43.43%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Axsome Therapeutics is more favorable than Bausch Health Companies.
Axsome Therapeutics has higher earnings, but lower revenue than Bausch Health Companies. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.
Axsome Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.
In the previous week, Bausch Health Companies had 3 more articles in the media than Axsome Therapeutics. MarketBeat recorded 5 mentions for Bausch Health Companies and 2 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.71 beat Bausch Health Companies' score of 0.27 indicating that Axsome Therapeutics is being referred to more favorably in the media.
81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Companies shares are held by institutional investors. 24.5% of Axsome Therapeutics shares are held by insiders. Comparatively, 8.1% of Bausch Health Companies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Axsome Therapeutics received 68 more outperform votes than Bausch Health Companies when rated by MarketBeat users. Likewise, 68.41% of users gave Axsome Therapeutics an outperform vote while only 62.06% of users gave Bausch Health Companies an outperform vote.
Bausch Health Companies has a net margin of -6.76% compared to Axsome Therapeutics' net margin of -88.41%. Bausch Health Companies' return on equity of 5,147.48% beat Axsome Therapeutics' return on equity.
Summary
Axsome Therapeutics beats Bausch Health Companies on 11 of the 18 factors compared between the two stocks.
Get Axsome Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Axsome Therapeutics Competitors List
Related Companies and Tools
